Balstilimab

Drug identity checked against registry records

Also recorded as AGEN2034

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal CancerNCT05608044AGENPhase 2Active not recruiting2027-09Estimated
A Study of Botensilimab (AGEN1181) for the Treatment of Advanced MelanomaNCT05529316AGENPhase 2Terminated2026-04-27Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.